Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Ind-Swift Laboratories Ltd

| Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Report Source

⬤31st Jan 26

Summary : Ind-Swift Laboratories reports positive Q3/9M FY26 results, completes amalgamation, and announces key board changes for strategic growth.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Cost of Materials Consumed, Purchase of stock in Trade, (Increase)/decrease in FG, WIP & stock in trade, Employee benefit, Finance Costs, Depreciation, Other expenditure.
  2. Standalone Q3 FY26 Revenue from operations: Rs. 14948.10 Lakhs (vs Rs. 12154.21 Lakhs in Q3 FY25).
  3. Consolidated Q3 FY26 Revenue from operations: Rs. 15085.34 Lakhs (vs Rs. 12879.86 Lakhs in Q3 FY25).
  4. Paid up Equity Share Capital (Standalone & Consolidated): Rs. 8161.16 Lakhs.
  5. Reserve excluding revaluation reserves (Standalone): Rs. 116407.81 Lakhs.
  6. Reserve excluding revaluation reserves (Consolidated): Rs. 117299.97 Lakhs.
  7. Mr. Navrattan Munjal (Chairman & Whole-Time Director) is the father of Mr. Sahil Munjal (Managing Director, Global Operations).
  8. Both standalone and consolidated unaudited financial results are presented.
  9. Consolidated results include Ind-Swift Laboratories Inc. USA, Fortune (India) Constructions Ltd, MJM Remedies Private Limited, ISLL Middle East LLC-FZ, Ind Swift India Ltd (Kenya) as subsidiaries.
  10. Consolidated results include Indis Healthcare LLP and Capital Strikers LLP as joint ventures.

Corporate Overview

  1. Manufacturing facilities in Punjab and Jammu & Kashmir (India).
  2. Subsidiaries in USA, Middle East, Kenya.
  3. Global operations and domestic business focus.
  4. Exclusively in the Pharmaceutical Business segment.
  5. Formal and informative, reporting board decisions and financial results.
  6. Focus on compliance with SEBI regulations.
  7. Revenue from operations
  8. Other Income
  9. Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab - 140507
  10. Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

Risk Factors

  1. No specific risks explicitly detailed in report.
  2. Auditor's review not full audit opinion.
  3. Website migration could cause temporary disruption.
  4. No explicit mention of market or industry risks.

Key Drivers

  1. Board restructuring for global and domestic growth.
  2. Amalgamation completed, equity shares listed.
  3. Strategic investments in AIFs and debentures.

Auditor’s Report

  1. Limited Review Report, not an audit opinion.
  2. No material misstatement found in the unaudited financial results.

Board Commentary

  1. Mr. Navrattan Munjal re-designated as Chairman and Whole-Time Director (effective Feb 1, 2026, until March 22, 2028).
  2. Mr. Himanshu Jain appointed as Managing Director (Domestic Operations) (effective Feb 1, 2026, until March 22, 2028).
  3. Mr. Sahil Munjal appointed as Managing Director (Global Operations) (effective Feb 1, 2026, until Feb 12, 2030).
  4. Remuneration approved for Mr. Rishav Mehta, Whole-Time Director, for remaining tenure (March 23, 2026, to March 22, 2028).
  5. Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  6. Preferential issue of 2,60,00,000 fully convertible warrants approved and allotted.
  7. Investment in 800 Non-Convertible Debentures (NCDs) of M/s. Ashok Investors Trust Ltd, 40 redeemed.
  8. Investment of Rs. 48.00 crores in Series B unsecured, unlisted and non-convertible debentures of M/s. Synthimed Labs Private Limited, fully redeemed.
  9. Authorized investment of up to Rs. 51 Crores in SEBI-registered AIFs, with Rs. 29.11 Crores invested in India Resurgence Fund II - Scheme I.

Corporate Governance

  1. Nomination and Remuneration Committee.
  2. Audit Committee.
  3. Investment Committee.

Management Discussion & Analysis

Future Strategy

  1. Board restructuring to drive sustainable growth and global expansion.
  2. Website migration from www.indswiftlabs.com to www.indswiftgroup.com by March 31, 2026.
  3. Strategic investments in SEBI-registered AIFs.

Operational Focus Areas

  1. Strengthening internal controls.
  2. Improving operational efficiency.
  3. Expanding business across India and globally.

Performance Drivers

  1. Strategic leadership for long-term growth and global presence.
  2. Strengthening internal controls and operational efficiency.
  3. Business expansion across domestic and international markets.